key: cord-0903985-uokpj3ae
authors: Grisold, Wolfgang; Moro, Elena; Teresa Ferretti, Maria; Hege Aamodt, Anne; Arabia, Gennarina; Lebedeva, Elena R.; Carvalho, Vanessa; Rakusa, Martin; Vonck, Kristl; Aybeck, Selma; Hassan Mansour, Alia; Goudier, Riadh; Giovannoni, Gavin; Jaarsma, Joke; Judit Molnar, Maria; Matczack, Magda; Bassetti, Claudio; de Visser, Marianne
title: Gender issues during the times of COVID‐19 pandemic
date: 2021-06-25
journal: Eur J Neurol
DOI: 10.1111/ene.14815
sha: 785e910229f05049c307e217b836a2ab332a62f5
doc_id: 903985
cord_uid: uokpj3ae

In this letter-to-the-editor the Task Force on Gender and Diversity issues in Neurology founded under the auspices of the European Academy of Neurology (EAN) addresses various gender issues that are arising during the COVID-19 pandemic. These issues concern different aspects, spanning from gender disparities in health care workforce to gender differences amongst patients suffering from COVID-19, risk factors, occurrence of neurological complications and (outcomes of) management. Due to the continuous flow of COVID-19 related papers this review cannot be comprehensive. We attempted to select the most relevant literature on this topic.

The global healthcare systems have a very high female gender workforce representation in all positions: from hospital aids and social workers to nurses and doctors [1] The double bind of professional roles and family and social roles is often a burden of females.

Family caregiving is also predominantly provided by women, although the role of men is gradually increasing, in particular in countries with an extensive social infrastructure [2] The COVID-19 pandemic has increased already existing gender inequality in the labour force with troubling consequences. Since women compose the majority of the health workforce they are more at risk of contracting SARS-CoV-2 given their prolonged close contact with patients. Based on data derived from the US COVID-19-Associated Hospitalization Surveillance Network (COVID-NET), nursing related occupations accounted for the largest proportion of COVID-19 hospitalized cases amongst healthcare professionals during 1 March to 31 May 2020 [3] These data highlight the importance of strict adherence to prevention measures including the availability of personal protective equipment.

The high physical and mental demands of caring for COVID -19 patients in hospitals and long-term care facilities have taken their toll, as shown by the high sick leave percentage amongst healthcare professionals worldwide and the high prevalence of burnout amongst Japanese front-line female workers [4] Of note, the virus might not be the only reason for the steep increase in sickness absence. It may also be due to underlying causes, such as staff shortages, preexisting workplace gender bias and inequities [5, 6] A recent review on articles concerning the identification of potential variables that influence mental health well-being during the COVID-19 pandemic in a broad array of women in healthcare showed that organizational factors were an important cause of stress and burnout [6] Resource adequacy related reasons (lack of protective personal equipment or staff shortages) and human resource related safety concerns (fear of getting infected with COVID-19 and thus putting family members at risk) were also major drivers of stress and burnout [6] Thus, there is an urgent need to further analyse and evaluate gender issues in the health and social sector workforce during this pandemic.

A study from the UK on 10,926 COVID-19 related deaths showed that age and male sex are risk factors for worse outcomes in COVID-19, with those aged 80 years and older having a 20 times higher risk compared with those aged 50-59 years and males having a higher risk than females (hazard ratio 1.59) [7] These gender differences are probably due to gender-specific behaviours, genetic and hormonal factors, and sex differences in biological pathways related to SARS-CoV-2 infection [8] Men are more likely to show smoking and alcohol consumption behaviours and have higher age- patients had severe disease. Amongst those with severe disease (defined by World Health Organization criteria for severe pneumonia), the pooled mean age was 60 years (compared with 44.6 years for those without severe disease) and more than half (61%) were male [9] Immunosuppression, diabetes and malignancy were most strongly associated with severe COVID-19, whereas older age, male gender, diabetes and hypertension were associated with higher mortality. Obesity or body mass index was not included in this analysis.

There is a host of publications on neurological complications of the COVID-19 infection. The percentage of neurological symptoms amongst the COVID-19 affected individuals varies widely (4.2%-87.3%) [10, 11] This can be ascribed to several methodological limitations [12] Therefore, Pezzini and Padovani caution against inferring any specific causal links between SARS-CoV-2 and neurological symptoms [12] The EAN core COVID-19 Task Force performed a multi-centre survey on neurological symptoms in SARS-CoV-2 patients of whom about half were polymerase chain reaction confirmed. The 2343 participants (82% were neurologists, mostly from Europe and in particular Italy) observed at least one neurological symptom in their patients (especially myalgia, headache, anosmia and ageusia).

Seventy-five per cent of the survey respondents were of the opinion that it was associated with the COVID-19 disease. No differences in gender were detected [13] A study composed of 1420 laboratory confirmed patients (962 females, 436 healthcare workers which is 30.7 % of the cohort) from 18 European hospitals focused on mild to moderate COVID-19 infection of which fewer than 10% required hospitalization [14] The most frequent symptoms were headache (70.3%), loss of smell (70.2%), nasal obstruction (67.8%), cough (63.2%), asthenia (63.3%), myalgia (62.5%), rhinorrhoea (60.1%), gustatory dysfunction (54.2%) and sore throat (52.9%). Loss of smell, headache, nasal obstruction, throat pain and fatigue were more prevalent in females (p < 0.001), whereas males more frequently suffered from cough and fever (p < 0.001) [14] In an American study composed of 509 hospitalized COVID-19 patients, each observed in more than five of the analysed studies and with an overall frequency of greater than 4% of the populations [19] Summarizing these results, smell and taste impairment is found to be a frequent feature in mildly affected patients, whereas other neurological manifestations such as headache, dizziness and impaired consciousness seem to be associated with severe disease.

Whether there is predominantly male involvement as is generally the case amongst COVID-19 infected patients cannot be confirmed. Unfortunately, possible gender disparities have often not been analysed. It might well be that systematic databases, such as the EAN COVID-19 Registry (ENERGY, https://wwwea norg/ean/ eanco re-covid -19), will help to further analyse the occurrence of neurological manifestations and the possible impact of gender [20] There are some reports of involvement of the peripheral nervous system, that is, Guillain-Barré syndrome cases or Miller-Fisher syndrome concomitantly with the COVID-19 spread, suggesting a pathogenic link [21, 22] However, a study from the UK did not find epidemiological or phenotypic clues of SARS-CoV-2 being causative of Guillain-Barré syndrome [23] Finally, long-COVID should be mentioned, which affects about 10% of individuals lasting for more than 28 days following a COVID-19 infection. The symptoms (fatigue, headache, dyspnoea, inability to concentrate and myalgia) show similarities with those associated with chronic fatigue syndrome. Those experiencing long-COVID were consistently older and more often female [24] Long-COVID-19 or post-COVID-19 neurological syndrome has as yet not been extensively researched.

Gender issues also play a role in the design of clinical trials. There are several factors why there may be gender differences in the design of trials. These factors can impact the eventual performance and acceptance of the novel drug [25] One of the factors is that women of childbearing age are usually excluded. However, pregnant or breastfeeding women were eligible for the randomized controlled trial investigating the efficacy of dexamethasone on the 28-day mortality in patients who were hospitalized with COVID-19 [26] Both the Food and Drug Administration and European Medicines 

Gender inequality during the COVID-19 crisis has been well recognized. Although in this paper our focus has been directed towards gender issues in patient care in general and neurology in particular, we would like to conclude with a quote from a United Nations development programme report that 'understanding gender-differentiated impacts of the COVID-19 crisis through sex-disaggregated data is fundamental to design policy responses that reduce vulnerable con- 

Gender equity in the health workforce: analysis of 104 countries. Working paper 1. Geneva: World Health Organization

Caregiving time costs and tradeoffs: gender differences in Sweden, the UK, and Canada. SSM -Popul Heal

COVID-NET Surveillance Team. COVID-19-Associated Hospitalizations Among Health Care Personnel -COVID-NET, 13 States

Prevalence of health care worker burnout during the coronavirus disease 2019 (COVID-19) pandemic in Japan

Sickness absence in healthcare workers during the COVID-19 pandemic

Women in Health Care Experiencing Occupational Stress and Burnout during COVID-19: A Review

Factors associated with COVID-19-related death using OpenSAFELY

COVID-19 and sex differences: mechanisms and biomarkers

Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes

New onset neurologic events in people with COVID-19 in 3 regions in China

Neurological symptoms in acute COVID-19 infected patients: a survey among Italian physicians

Lifting the mask on neurological manifestations of COVID-19

The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection

Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019

Frequent neurologic manifestations and encephalopathyassociated morbidity in COVID-19 patients

Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Central nervous system manifestations in COVID-19 patients: a systematic review and meta-analysis

A systematic review of neurological symptoms and complications of COVID-19

NeuroCOVID: it's time to join forces globally

Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic

Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions

Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome

Attributes and predictors of long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study app

Gender differences and clinical trial design

Dexamethasone in hospitalized patients with COVID-19

The influence of sex and gender on the immune response

Lack of consideration of sex and gender in clinical trials for COVID-19